Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18609360 | 0.81 | OPRK1 (0.32) | OPRK1DPP4NCF1 | |
| SCHEMBL102076 | 0.78 | NCF1 (0.52) | OPRK1NCF1 | |
| SCHEMBL24031886 | 0.77 | LMNA (0.30) | — | |
| SCHEMBL27425082 | 0.76 | ACHE (0.34) | OPRK1PIK3CDNCF1 | |
| SCHEMBL102379 | 0.76 | HRH3 (0.42) | OPRK1 | |
| SCHEMBL2461 | 0.76 | — | — | |
| SCHEMBL21775731 | 0.76 | OPRK1 (0.34) | OPRK1 | |
| SCHEMBL25075126 | 0.76 | ACHE (0.33) | OPRK1 | |
| SCHEMBL19268062 | 0.74 | OPRM1 (0.33) | OPRK1PIK3CD | |
| SCHEMBL1621207 | 0.74 | PIK3CD (0.42) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2022125925-A1 | COMPOSITIONS FOR TREATING DRY AGE-RELATED MACULAR DEGENERATION (AMD) | COGNITION THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| EP-3307742-B1 | METHODS OF TREATING OR PREVENTING A PROTEOPATHY | USHER III INITIATIVE INC (US) | 2022-05-18 | — | — | EP | disclosed |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200291007-A1 | BENZIMIDAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CAPELLA THERAPEUTICS, INC. | 2020-09-17 | — | — | US | disclosed |
| US-10688082-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10647707-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180193314-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-07-12 | — | — | US | disclosed |
| US-10011615-B2 | Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170197991-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2017-07-13 | — | — | US | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688082-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | OPRK1 129/4885PIK3CD 3426/4885DPP4 2238/4885 |
| US-20180193314-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | OPRK1 129/4885PIK3CD 3426/4885DPP4 2238/4885 |
| US-10647707-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | OPRK1 2113/4885PIK3CD 131/4885DPP4 2188/4885 |
| US-20170197991-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | OPRK1 67/4885PIK3CD 1833/4885DPP4 1580/4885 |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | OPRK1 2246/4885PIK3CD 134/4885DPP4 2026/4885 |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | OPRK1 2089/4885PIK3CD 140/4885DPP4 2326/4885 |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | OPRK1 2089/4885PIK3CD 140/4885DPP4 2326/4885 |
| US-20200291007-A1 | BENZIMIDAZOLE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | CCNI, CYP2C19, PHB1 | OPRK1 3101/4885PIK3CD 1285/4885DPP4 558/4885 |
| US-10011615-B2 | Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties | ADORA2A, ADORA3, ADORA1 | OPRK1 64/4885PIK3CD 2144/4885DPP4 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.